Good MorningWild swings continued on Wall Street on Thursday. TheS&P 500 reversed an early loss to gain more than 1.85% at the high of the day. The move came despite a round of mixed economic data that suggest weaker than expected job creation on the heels of the largest increase in wage inflation ever recorded in the US. US wages rose 12.6% in Q1 to drive a similarly large contraction in productivity. The takeaway from the data is that economic activity is contracting due to the rise in inflation, specifically wage inflation, and the data will most likely get worse before it gets better.
Next week, the market will be on high alert for the Consumer Price Index. The index is expected to make a sharp slowdown from previous months due to the overlap with last year's data. The risk for the market is that inflation will not cool appreciably and add pressure on the Fed. This will be the last inflation data before the next FOMC meeting, the FOMC is expected to hike rates by 50 basis points with a near 100% certainty. Featured: Seven gold miners. One pattern. [look what happened to each] (Ad) 
|
Consumer Discretionary | |
RH Falls On Soft Outlook, Weakening Demand Trends
RH (NYSE: RH) was one of the first companies to warn the market about inflationary and supply chain hiccups and, as such, we expect to see give some of the earliest insight into what to expect over the summer. As dubious as the company’s be... Read the Full Story |
|
From Our Partners | | Hedge funds are rotating out of AI hype and into the hardware layer powering it. New research identifies three profitable U.S. infrastructure companies leading this shift.
One just posted 76% year-over-year data-center growth. Another holds a $12 billion backlog from global hyperscalers. A third is generating 59%+ gross margins on next-gen chips. | | Access the full analysis, price setups, and catalysts now |
|
Technology | |
Xiaomi Co. (OTCMKTS:XIACF) is currently down 35.70% YTD as it struggles with global macroeconomic headwinds. During the company’s most recent earnings call, Xiaomi gave reasons for its underperformance. Executives stated that the resurgence of COVID-19 and the shortage of key components are ... Read the Full Story |
|
Technology | |
After a vicious selloff that saw shares of identity software company Okta (NASDAQ: OKTA) fall 70% from last November through last month, they’re finally looking like they’re ready to turn around. Investors have to go all the way back to January to find a run of two green weeks in a row... Read the Full Story |
|
From Our Partners | | Jon Najarian called Tesla a buy in 2014 before the stock climbed as high as 3,392%. He also called Palantir on live TV in 2020 before it surged as high as 2,000%.
Now Najarian has a new prediction centered on Elon Musk - tied to the anticipated SpaceX IPO and what he describes as a potential $44 trillion opportunity. He's sharing the specific moves he thinks investors should consider making now. | | See exactly what Jon Najarian is predicting about SpaceX and Musk |
|
Consumer Discretionary | |
Chinese tech stocks such as Alibaba Group (NYSE: BABA) have faced a number of headwinds recently that have negatively affected the companies' stock prices. These headwinds include regulatory pressures and China’s links with Russia. The Hang Seng China Enterprises index which tracks Chinese s... Read the Full Story |
|
Consumer Discretionary | |
As long as short interest remains high, the overall view of CHWY stock is cloudy
Shareholders in Chewy (NYSE: CHWY) are getting some relief from the relentless sell-off in the stock. In late-day trading, CHWY stock is up 23.8% on the back of a strong earnings report. The online retailer of all t... Read the Full Story |
|
From Our Partners | | Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years. | | Get the seven high-yield dividend stocks free now |
|
Consumer Staples | |
Hormel Foods Falls On Inflation Concerns
Hormel Foods (NYSE: HRL) did not have a bad quarter or even give poor guidance but the Q2 results are a message for the market. Not only is inflation cutting into volume sales and profits but even higher prices are on the way for US consumers. The key take... Read the Full Story |
|
Technology | | Software development applications platform JFrog (NASDAQ: FROG) stock has been pummeled falling over (-70%) off its post-IPO highs in the technology bear market. DevOps platforms can speed up software development times from months to hours and enable continuous software releases. It optimizes and st... Read the Full Story |
|
Consumer Discretionary | |
PVH Corp. Has What It Takes To Win In Tough Times
We were not surprised to see PVH Corp. (NYSE: PVH) post strong results and guidance, not after competitor Ralph Lauren did the same. The two share a few traits common among today’s retail winners including brands that resonate, a focus on e... Read the Full Story |
|
Technology | |
But NetApp Is Still A Buy
The analysts are reeling in their targets for NetApp (NASDAQ: NTAP) but the stock is still a buy. At least 5 of the 21 analysts covering the stock have come out in the wake of the FQ4 earnings report and they all include price target reductions. The takeaway from the ac... Read the Full Story |
|
Consumer Discretionary | |
Gamestop Is No Stock We Want To Own
The only thing we can guarantee about the Gamestop (NYSE: GME) market is that the wild swings in volatility are not over. While the company may be working hard on improving itself, there is still no fundamental reason to own the stock and Wall Street’s ... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
